MEDCO CONTAINMENT NAMES ROBERT LEVENSON SENIOR EXEC VP
MEDCO CONTAINMENT NAMES ROBERT LEVENSON SENIOR EXEC VP and chief operating officer, the company announced Sept. 20. Levenson, 49, was previously group president and a board member of Roseland, N.J.-based Automatic Data Processing Inc., an independent computing services firm specializing in payroll processing. At Medco, Levenson succeeds former Senior Exec VP Ron Kalish, 50, who will act as a senior consultant to the company. Levenson joined Automatic Data Processing in 1981; he was elected to ADP's board in 1985 and named president of the specialized services group in December 1988. ADP reported FY 1990 revenues of $1.7 bil. for the year ended June 30. The appointment of Levenson by Fair Lawn, N.J.-based Medco Containment Services is one of several changes at the senior management level effective Oct. 1. The company also has created an office of the president, which consists of Levenson; Senior Exec VP and Chief Financial Officer James Manning, 43; and Per G. H. Lofberg, 43, who is promoted to senior exec VP-strategic planning and marketing. The office of the president handles Medco's "day-to-day operations" and its members report to Chairman/CEO Martin Wygod, 50. Senior Exec VP-Sales Donald Dahlin also reports to Wygod. According to the firm, the reorganization will "expedite decision making and will permit Mr. Wygod to concentrate on strategic management areas and to work directly with Mr. Dahlin on new sales." Medco recently reported FY 1990 (ended June 30) sales of$1 bil., a 38% increase over FY 1989 sales of $728 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth